Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.

@article{Jabbour2007NovelTK,
  title={Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.},
  author={Elias J Jabbour and Jorge E. Cortes and Hagop M Kantarjian and Sergio Giralt and Borje S. Andersson and F. R. Giles and Elizabeth J Shpall and Partow Kebriaei and Richard Champlin and Marcos de Lima},
  journal={Cancer},
  year={2007},
  volume={110 2},
  pages={340-4}
}
BACKGROUND Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) are increasingly likely to have received a novel tyrosine kinase inhibitor (NTKI) after failing imatinib mesylate. It is unknown whether the use of these NTKIs before HSCT increases transplant-related toxicity. METHODS The outcome of 12 patients with CML (1 in chronic phase, 6 in the accelerated phase, and 5 in the blastic phase) who received dasatinib (n = 2), nilotinib… CONTINUE READING